Why I’d dump the Metro Bank share price and buy the RBS share price right now

Rupert Hargreaves explains why he believes Metro Bank is a poor investment compared to RBS, which offers much more profit potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Metro Bank (LSE: MTRO), one of the UK’s leading challenger banks, have fallen around 90% from their all-time high over the past 18 months. 

Following this decline, the stock looks attractive as a value investment. However, while the shares might seem cheap at first glance, it is essential to remember why investors have turned their backs on the business in the first place. 

Struggling business

At the beginning of 2018, Metro was flying high. The bank was meeting or exceeding its growth objectives, and it looked as if the group’s growth was unstoppable.

For the first quarter of 2018, Metro reported a 41% year-on-year increase in customer deposits, lending growth of 69% and an underlying profit before tax of £10m for the quarter. 

The firm’s growth story began to unravel in the first half of 2018. Soon after commenting that the group had plenty of capital to fulfil its expansion plans, management announced a £9m placing of new shares representing approximately 10% of the company’s issued share capital to bolster its balance sheet at the end of July.

Then in the third quarter, growth started to slow. Deposit growth halved in Q3 2018. 

Metro’s problems only got worse in the first half of 2019. The company revealed that it had miscalculated the strength of its balance sheet and was forced to ask shareholders for £350m of extra capital in May. The revelation shocked investors and customers. 

A better buy 

Since May, Metro has been working hard to try to restore investor and customer confidence. Nevertheless, it’s clear to me that this bank will never be able to rebuild the sort of reputation it had at the beginning of 2018. 

And with this being the case, I think it would be wise for investors to avoid the challenger bank altogether and invest in Royal Bank of Scotland (LSE: RBS) instead.

You see, while Metro looks cheap, trading at a price-to-tangible-book-value of just 0.3, RBS is just as undervalued. Shares in the bank are currently dealing at a price-to-tangible-book-value of 0.6 and RBS has other attractive qualities, such as dividends. 

For 2019, City analysts believe that the bank will return a total of 24p per share, giving a dividend yield of 12.2% on the current price. Analysts are expecting a total dividend of 16.7p for 2020, a potential dividend yield of 8.6%

Rising profits 

What’s more, unlike Metro, RBS is highly profitable. Analysts believe the bank will report a net income of £3.4bn for 2019. That puts the stock on a forward P/E of 7.6.

Of course, RBS does also have its own problems. Brexit uncertainty, regular IT problems and a low return on equity are all issues for the bank, but compared to Metro, it looks to me to be the much better bet. The group’s balance sheet is much stronger, it is much more profitable, and RBS is returning capital to shareholders.

Overall, if you are looking for an undervalued banking stock to add to your portfolio today, I reckon RBS would be a better buy than Metro. Even though Metro looks deeply undervalued, it’s questionable if the bank can ever return to its former glory.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »